3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Glioblastoma
7
Recurrence
2
Prostatic Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Optic Nerve Glioma
1
Oligodendroglioma
1
Metatropic dwarfism
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Leukemia, Eosinophilic, Acute
1
Leukemia, Basophilic, Acute
1
Gliosarcoma
1
Glioma
1
Diffuse Intrinsic Pontine Glioma
1
Congenital Abnormalities
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
361
Pemetrexed
276
Cisplatin
230
Paclitaxel
213
Docetaxel
205
Gemcitabine
160
Erlotinib Hydrochloride
150
Bevacizumab
132
pembrolizumab
129
Radiotherapy
114
Nivolumab
88
durvalumab
84
Drug Therapy
84
osimertinib
82
atezolizumab
58
Vinorelbine
53
Gefitinib
53
Radiosurgery
50
Cetuximab
39
Taxes
37
130-nm albumin-bound paclitaxel
36
Ipilimumab
34
anlotinib
33
Surgical Procedures, Operative
33
Magnetic Resonance Spectroscopy
33
Etoposide
30
Albumin-Bound Paclitaxel
29
tislelizumab
27
icotinib
27
aflutinib
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Non-Small-Cell Lung
×
Cilengitide
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts